Rhythm Pharmaceuticals Inc’s filing revealed that its Chief Financial Officer Smith Hunter C unloaded Company’s shares for reported $0.13 million on Feb 19 ’25. In the deal valued at $57.22 per share,2,215 shares were sold. As a result of this transaction, Smith Hunter C now holds 109,929 shares worth roughly $5.76 million.
Then, Shulman Joseph sold 1,228 shares, generating $70,266 in total proceeds. Upon selling the shares at $57.22, the Chief Technical Officer now owns 8,509 shares.
Before that, Meeker David P sold 9,896 shares. Rhythm Pharmaceuticals Inc shares valued at $566,249 were divested by the President and CEO at a price of $57.22 per share. As a result of the transaction, Meeker David P now holds 201,281 shares, worth roughly $10.55 million.
Jefferies initiated its Rhythm Pharmaceuticals Inc [RYTM] rating to a Buy in a research note published on January 02, 2025; the price target was $80. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. Guggenheim began covering RYTM with “Buy” recommendation on October 21, 2024. H.C. Wainwright started covering the stock on September 18, 2024. It rated RYTM as “a Buy”.
Price Performance Review of RYTM
On Monday, Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] saw its stock fall -4.57% to $52.40. Over the last five days, the stock has lost -4.13%. Rhythm Pharmaceuticals Inc shares have fallen nearly -6.40% since the year began. Nevertheless, the stocks have risen 18.07% over the past one year. While a 52-week high of $68.58 was reached on 02/05/25, a 52-week low of $35.17 was recorded on 02/25/25. SMA at 50 days reached $56.78, while 200 days put it at $50.75.
Levels Of Support And Resistance For RYTM Stock
The 24-hour chart illustrates a support level at 51.03, which if violated will result in even more drops to 49.65. On the upside, there is a resistance level at 54.59. A further resistance level may holdings at 56.77. The Relative Strength Index (RSI) on the 14-day chart is 38.49, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.67%. Stochastics %K at 31.96% indicates the stock is a holding.
The most recent change occurred on September 17, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $64 price target.
